Antibody

APP or β-Amyloid (4G8)

Clonality: monoclonal
Host: Mouse
Isotype: IgG2b
Methods: ELISA, IH, IP, WB
Source: BioLegend
Cat# 800708 (50 µl) RRID AB_2734547
Cat# 800709 (200 µl) RRID AB_2565325
Cat# 800710 (500 µl) RRID AB_2565326
Cat# 800711 (1 ml) RRID AB_2565324
Previously Covance Cat# SIG-39200
Formulation: crude ascites
Reactivity:
Reacts in: Human, Mouse
Availability: Available from BioLegend

Immunogen/Epitope

epitope within amino acids 18-23 of the Aβ peptide

Specificity

reactive to amino acids 17-24 of Aβ and to APP

Comments / Questions

No Available Comments

Make a comment or submit a question

To make a comment you must login or register.

References

No Available References

Further Reading

Papers

  1. . Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol. 2010 Aug;68(2):220-30. PubMed.
  2. . Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet. 2007 Dec;39(12):1440-2. PubMed.
  3. . Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007 Nov;117(11):3393-402. PubMed.
  4. . Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem. 2007 Jun 29;282(26):18895-906. PubMed.
  5. . Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 2007 Sep 14;282(37):26832-44. PubMed.